needleless injections going AMEX!!!
Business/Technology Editors & Health/Medical Writers
WESTFORD, Mass.--(BW HealthWire)--Dec. 8, 2000--EQUIDYNE
CORPORATION (OTCBB:INJX) announced today the approval of its
application for its shares of common stock to be traded on the
American Stock Exchange (AMEX). Equidyne's shares will be traded on
the AMEX under the symbol "IJX", effective December 15, 2000
J. Randall Nelson, President and Chief Executive Officer, stated,
"The listing of our common stock on the AMEX will give the Company
greater visibility and stature in the financial community. This
graduation is in many ways a result of the remarkable progress the
company has made over the past twelve months."
Nelson continued, "An AMEX listing will expose Equidyne and its
INJEX(TM) needle-free system to a much broader group of investors,
many of whom have been precluded from acquiring Equidyne's stock while
it was listed on the OTC Bulletin Board. We believe this listing will
result in a more appropriate valuation of our INJEX(TM) technology and
the additional value created as a result of the sale of our $50
million investment in Rosch AG Medizintechnik, and the launch of the
INJEX(TM) System into the U.S. diabetes market."
Trading data on the AMEX is widely distributed by wire services
for dissemination by newspapers and other media. Equidyne's entry to
the AMEX also provides additional advantages with respect to
compliance with blue-sky regulations of various states and the margin
requirements of the Federal Reserve.
Equidyne Corporation, through Equidyne Systems, Inc., a
wholly-owned subsidiary based in San Diego, California is focused on
becoming the worldwide leader in needle-free drug delivery systems for
subcutaneous and intramuscular injections. The INJEX(TM) needle-free
injector is a compact, uncomplicated device that delivers a virtually
painless injection through the skin in a fraction of a second, and
eliminates needle stick and disposal problems. For medications
requiring injection, we believe the INJEX(TM) System is by far the
most comfortable and economical product on the market.
The statements contained in this news release that are not purely
historical are forward-looking statements that may involve risks and
uncertainties. The Company's actual results may differ significantly
from the results contained in the forward-looking statements. Factors
that might cause such differences include, but are not limited to, the
effect of losses and other factors on the Company's credit facilities,
business and results of operations; the Company's limited capital
resources and its ability to fulfill its existing obligations and
ongoing capital needs; risks associated with excess or obsolete
inventory; the potential impairment of assets; the Company's
dependence on key customers and their financial viability; the impact
of competition; and the Company's abilities to effectively manage
growth. These and other risk factors are discussed in the Company's
filings on Forms 8-K, 10-QSB and 10-KSB.
--30--bh/bos*
CONTACT: Michael T. Pieniazek
Equidyne Corporation
(978) 692-6680
or
Jeffery Lamberson or Richard Carpenter
American Financial Communications
(415) 380-3880
KEYWORD: MASSACHUSETTS
INDUSTRY KEYWORD: MEDICAL MEDICAL DEVICES
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com |
